Latrepirdine for Alzheimer's disease

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 4, 2015, Pages

  Chau, Sarah ^a   Herrmann, Nathan ^a   Ruthirakuhan, Myuri T ^a   Chen, Jinghan Jenny ^a   Lanctôt, Krista L ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Sunnybrook Health Sciences Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIMEBON; PLACEBO; INDOLE DERIVATIVE; NOOTROPIC AGENT;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; BEHAVIOR; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INTENTION TO TREAT ANALYSIS; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; XEROSTOMIA; DRUG EFFECTS; META ANALYSIS; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ALZHEIMER DISEASE; BEHAVIOR; COGNITION; HUMANS; INDOLES; NOOTROPIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84944463011     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009524.pub2     Document Type: Review

References (42)

1. Cano-Cuenca N, Solis-Garcia del Pozo JE, Jordan J. Evidence for the efficacy of latrepirdine (dimebon) treatment for improvement of cognitive function: a meta-analysis. Journal of Alzheimer's Disease 2014;38:155-65.
2. Medivation, Inc, Pfizer. CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease on Donepezil. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009-[cited 2014 Jun 4]. Available from: http://clinicaltrials.gov/ct2/show/NCT00829374 NLM Identifier: NCT00829374.
3. Cano-Cuenca N, Solis-Garcia del Pozo JE, Jordan J. Evidence for the efficacy of latrepirdine (dimebon) treatment for improvement of cognitive function: a meta-analysis. Journal of Alzheimer's Disease 2014;38:155-65.
4. Medivation, Inc, Pfizer. A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease (CONNECTION). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2008-[cited 2014 Jun 4]. Available from: http://clinicaltrials.gov/ct2/show/NCT00675623 NLM Identifier: NCT00675623.
5. Medivation, Inc, Pfizer. A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease (CONTACT). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2008-[cited 2014 Aug 18]. Available from: http://clinicaltrials.gov/show/NCT00954590 NLM Identifier: NCT00954590.
6. Doody R, Gavrilova S, Sano M, Thomas RG, Aisen PS, Bachurin SO, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimers disease: a randomised, double-blind, placebo-controlled study. Lancet 2008;372:207-15.
7. Pfizer, Medivation, Inc. A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009-[cited 2014 Jun 4]. Available from: http://clinicaltrials.gov/ct2/show/NCT0083811 NLM Identifier: NCT00838110.
8. Medivation, Inc, Pfizer. A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 26-Week Trial To Evaluate The Efficacy And Safety Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2008-[cited 2014 Aug 18]. Available from: http://clinicaltrials.gov/show/NCT00912288 NLM Identifier: NCT00912288.
9. Tariot P, Sabbagh M, Flitman S, Reyes P, Taber I, Seely L. A safety, tolerability and pharmacokinetic study of dimebon in patients with Alzheimer's disease already receiving donepezil. Alzheimer's & Dementia 2009;5 Suppl:P251.
10. Alzheimers Association. 2010 Alzheimer's disease facts and figures. Alzheimer's & Dementia 2010;6(2):158-94.
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th Edition. Arlington, VA: American Psychiatric Publishing, 2013.
12. Anderton BH, Betts J, Blackstock WP, Brion JP, Chapman S, Connell J, et al. Sites of phosphorylation in tau and factors affecting their regulation. Biochemical Society Symposia 2001;67:73-80.
13. Ankri J, Beaufils B, Novella J-L, Morrone I, Guillemin F, Jolly D, et al. Use of the EQ-5D among patients suffering from dementia. Journal of Clinical Epidemiology 2003;56(11):1055-63.
14. Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Annals of the New York Academy of Sciences 2001;939:425-35.
15. Bachurin S, Shevtsova E, Kireeva E, Oxenkrug G, Sablin S. Mitochondria as a target for neurotoxins and neuroprotective agents. Annals of the New York Academy of Sciences 2003;993:334-44.
16. Bassil N, Grossberg G. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs 2009;23(4):293-307.
17. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue Art. No.: CD005593.
18. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimers disease. Alzheimer's & Dementia 2007;3:186-91.
19. Cano-Cuenca N, Solis-Garcia del Pozo JE, Jordan J. Evidence for the efficacy of latrepirdine (dimebon) treatment for improvement of cognitive function: a meta-analysis. Journal of Alzheimer's Disease 2014;38:155-65.
20. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14.
21. Cummings JL, Donahue JA, Brooks RL. The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease. The American Journal of Geriatric Psychiatry 2000;8(2):134-40.
22. Finkel SI. Effects of rivastigmine on behavioural and psychological symptoms of dementia in Alzheimer's disease. Clinical Therapeutics 2004;26(7):980-90.
23. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975;12:189-98.
24. Galasko D, Bennett D, Sano M. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders 1997;11 Suppl 2:S33-9.
25. Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, for the GRADE Working Group. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
26. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics. Science 2002;297:353-6.
27. Henzel A, Angermeyer MC, Riedel-Heller SG. Measuring cognitive change in older adults: reliable change indices for the Mini-Mental State Examination. Journal of Neurology, Neurosurgery, and Psychiatry 2007;78(12):1298-303.
28. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org. The Cochrane Collaboration.
29. Jones R. Dimebon disappointment. Alzheimer's Research & Therapy 2010;2:25.
30. Kanamarua Y, Kikukawaa A, Miyamotoa Y, Hirafujib M. Dimenhydrinate effect on cerebral oxygen status and salivary chromogranin-A during cognitive tasks. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008;32(1):107-15.
31. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurology 2010;9(7):702-16.
32. McGreer PL, McGreer EG. NSAIDs and Alzheimer's disease: epidemiological, animal, model and clinical studies. Neurobiology of Aging 2007;28(5):639-47.
33. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939-44.
34. McShane R, Sastre AA, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006, Issue Art. No.: CD003154.
35. Rafii M, Aisen P. Recent developments in Alzheimer's disease therapeutics. BMC Medicine 2009;7:7.
36. Reisberg B, Schneider L, Doody R. Clinical global measures of dementia: position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Disease and Associated Disorders 1997;11 Suppl 3:8-18.
37. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders 1997;11 Suppl 2:S22-32.
38. Schrag A, Schott JM. What is the clinically relevant change on the ADAS-Cog?. Journal of Neurology, Neurosurgery, and Psychiatry 2012;83(2):171-3.
39. Wang J, Ferruzzi MG, Varghese M, Qian X, Cheng A, Xie M, et al. Preclinical study of dimebon on B-amyloid-mediated neuropathy in Alzheimer's disease. Molecular Neurodegeneration 2011;6(1):7.
40. Weyer G, Erzigkeit H, Kanowski S, Ihl R, Hadler D. Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial. International Psychogeriatrics 1997;9:123-38.
41. Wimo A, Jonsson L, Zbrozek A. The resource utilization in dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementia. Journal of Nutrition 2010;14(8):685-90.
42. Wu J, Li Q, Bezprozvanny I. Evaluation of Dimebon in cellular model of Huntington's disease. Molecular Neurodegeneration 2008;3:15.